Affordable Access

Access to the full text

Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study

Authors
  • Adamashvili, Irena1
  • Minagar, Alireza1
  • Gonzalez-Toledo, Eduardo2
  • Featherston, Liubov1
  • Kelley, Roger E1
  • 1 LSU Health Sciences Center, Department of Neurology, 1501 Kings Highway, Shreveport, LA, 71130, USA , Shreveport
  • 2 LSU Health Sciences Center, Department of Radiology, 1501 Kings Highway, Shreveport, LA, 71130, USA , Shreveport
Type
Published Article
Journal
Journal of Neuroinflammation
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jun 02, 2005
Volume
2
Issue
1
Identifiers
DOI: 10.1186/1742-2094-2-13
Source
Springer Nature
Keywords
License
Yellow

Abstract

BackgroundMeasurement of soluble HLA in body fluids has a potential role in assessing disease activity in autoimmune disorders.MethodsWe applied a solid phase, enzyme-linked immunoassay to measure soluble HLA class I (sHLA-I) and class II (sHLA-II) molecules in the saliva and cerebrospinal fluid (CSF) in 13 untreated patients with relapsing-remitting form of multiple sclerosis (MS). For comparison purposes, we also studied saliva from 53 healthy subjects.ResultsSaliva from normal controls had detectable sHLA-I levels in 41 of 53 individuals studied, with values ranging from 9–100 ng/ml (mean = 41 ± 2.8 ng/ml). sHLA-I was undetectable in the saliva in 11 of 13 MS patients, and in none of the CSF specimens. In contrast, mean sHLA-II concentration in the saliva of MS patients was significantly increased compared to controls (386 ± 52 unit/ml vs. 222 ± 18.4 unit/ml, t = 8.68, P < 0.005). The mean CSF sHLA-II level (369 ± 16 unit/ml) was equivalent to the mean sHLA-II concentration measured in saliva (mean = 386 ± 52 unit/ml) (P = 0.7). In patients with brain magnetic resonance imaging (MRI) enhancing lesions (n = 5), reflective of more active disease, CSF sHLA-II averaged 356 ± 26 unit/ml compared to 380 ± 51 in saliva. Similarly, in patients with non-enhancing lesions (n = 8), CSF sHLA-II averaged 377 ± 18 unit/ml compared to 390 ± 77 unit/ml in saliva. Thus, the mean sHLA-II concentration in saliva and CSF was essentially equivalent for MS patients with or without enhancing plaques.ConclusionOur data suggest that the measurement of soluble HLA in saliva, specifically sHLA-II, correlates with the level found in the CSF. Therefore, if sHLA correlates with disease activity in MS, as has been proposed, saliva measurements provide a noninvasive correlate of CSF measurement.

Report this publication

Statistics

Seen <100 times